Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Michael Eisenstein is a freelance writer based in Philadelphia, Pennsylvania.
You can also search for this author in PubMed Google Scholar
In January 2023, Oregon is due to embark on a groundbreaking real-world experiment in psychedelic medicine. This follows a ballot measure in 2020, in which voters called on the state to begin creating the infrastructure needed to make the hallucinogenic drug psilocybin available as a treatment for mental-health disorders such as depression and anxiety. Canada made a similar move in January 2022, albeit with far more restrictions, allowing designated clinicians to prescribe psilocybin to people with debilitating mental illnesses, such as severe, treatment-resistant depression.
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 609, S87-S89 (2022)
doi: https://doi.org/10.1038/d41586-022-02872-9
This article is part of Nature Outlook: Psychedelic medicine, an editorially independent supplement produced with the financial support of third parties. About this content.
Carhart-Harris, R. L. et al. Lancet Psychiat. 3, 619–627 (2016).
Article Google Scholar
Davis, A. K. et al. JAMA Psychiatry 78, 481–489 (2021).
Article PubMed Google Scholar
Carhart-Harris, R, et al. N. Engl. J. Med. 384, 1402–1411 (2021).
Article PubMed Google Scholar
Gukasyan, N. et al. J. Psychopharmacol. 36, 151–158 (2022).
Article PubMed Google Scholar
Shao, L.-X. et al. Neuron 109, 2535–2544 (2021).
Article PubMed Google Scholar
Grob, C. S. et al. Arch. Gen. Psychiat. 68, 71–78 (2011).
Article PubMed Google Scholar
Ross, S. et al. J. Psychopharmacol. 30, 1165–1180 (2016).
Article PubMed Google Scholar
Griffiths, R. R. et al. J. Psychopharmacol. 30, 1181–1197 (2016).
Article PubMed Google Scholar
Download references
Psychedelic medicine faces the acid test
Taking the tripping out of psychedelic medicine
Hope that psychedelic drugs can erase trauma
How MDMA resensitizes the brain
Finding medical value in mescaline
Your brain on psychedelics
Psychedelic research and the real world
Psychedelic microdosing hits a rough patch in clinical trials
Research round-up: psychedelic medicine
The psychedelic remedy for chronic pain
Can psychedelic drugs uncover the secrets of consciousness?
Sponsor feature: Why regulators say now is the time to explore psychedelics
CRISPR cures and cancer vaccines: researchers can help to shepherd them to market
Editorial
AI finds huge cache of anti-bacterial peptides hidden in genomic data
Research Highlight
Randomized trials of cancer drugs are for yesterday
Outlook
MDMA therapy for PTSD rejected by FDA panel
News
Internet use and teen mental health: it’s about more than just screen time
Correspondence
Social-media influence on teen mental health goes beyond just cause and effect
Correspondence
MDMA therapy for PTSD rejected by FDA panel
News
Autistic people three times more likely to develop Parkinson’s-like symptoms
News
Neural pathways for reward and relief promote fentanyl addiction
News & Views
Postdoctoral positions funded by NIH are for study of meiosis and spermatogonial stem cells using mouse models. Generous stipend and benefits.
Philadelphia, Pennsylvania (US)
University of Pennsylvania – Department of Biomedical Sciences
Associate or Senior Editor (Materials Science) Organization: Nature Communications Location(s): New York, Jersey City, Philadelphia, Beijing, Hong …
New York (US)
Springer Nature Ltd
Associate or Senior, Nature Medicine: Infectious Diseases New York, Shanghai or Beijing – Hybrid Working Application Deadline: August 1, 2024 Nat…
New York City, New York (US)
Springer Nature Ltd
Funded investigator has an immediate opening for a post-doctoral fellow to develop therapies for genetic diseases.
Johns Hopkins School of Medicine, East Baltimore Campus
Johns Hopkins University Department of Medicine
Houston, Texas (US)
Baylor College of Medicine (BCM)
Psychedelic medicine faces the acid test
Taking the tripping out of psychedelic medicine
Hope that psychedelic drugs can erase trauma
How MDMA resensitizes the brain
Finding medical value in mescaline
Your brain on psychedelics
Psychedelic research and the real world
Psychedelic microdosing hits a rough patch in clinical trials
Research round-up: psychedelic medicine
The psychedelic remedy for chronic pain
Can psychedelic drugs uncover the secrets of consciousness?
Sponsor feature: Why regulators say now is the time to explore psychedelics
An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.
© 2024 Springer Nature Limited